New biomarkers and targets in pancreatic cancer and their application to treatment

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 8, 2012, Pages 435-444

  Costello, Eithne ^a   Greenhalf, William ^a   Neoptolemos, John P ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CD40 ANTIGEN; CYCLOPAMINE; DRUG METABOLIZING ENZYME; EPITHELIAL CELL ADHESION MOLECULE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; ERLOTINIB; FGK 45; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INIPARIB; IRINOTECAN; K RAS PROTEIN; MICRORNA; MICRORNA 10B; MRK 0003; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOTCH RECEPTOR; NUCLEOTIDE TRANSPORTER; OXALIPLATIN; PACLITAXEL; PROTEIN RET; SONIC HEDGEHOG PROTEIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VANDETANIB;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CACHEXIA; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CIRCULATING TUMOR CELL; DIARRHEA; DISEASE MARKER; DRUG DESIGN; DRUG INDICATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; EARLY CANCER; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GENETIC HETEROGENEITY; HUMAN; MATHEMATICAL MODEL; METASTASIS; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STOMATITIS; SURVIVAL PREDICTION; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; CARCINOMA IN SITU; CARCINOMA, PANCREATIC DUCTAL; COMPUTATIONAL BIOLOGY; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; EQUILIBRATIVE NUCLEOSIDE TRANSPORT PROTEINS; FLUOROURACIL; GENE REARRANGEMENT; HEDGEHOG PROTEINS; HUMANS; MICRORNAS; PANCREATIC NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84864857745     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.119     Document Type: Review

References (96)

1. Ferlay, J., Parkin, D.M. & Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. Eur.J. Cancer 46, 765-781 (2010).
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012).
3. Vincent, A., Herman, J., Schulick, R., Hruban, R.H. & Goggins, M. Pancreatic cancer. Lancet 378, 607-620 (2011).
4. Lemmens, V.E. et al. Improving outcome for patients with pancreatic cancer through centralization. Br.J. Surg. 98, 1455-1462 (2011).
5. Ghaneh, P., Costello, E. & Neoptolemos, J.P. Biology and management of pancreatic cancer. Gut 56, 1134-1152 (2007). (Pubitemid 47123247)
6. Neoptolemos, J.P. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.N. Engl.J. Med. 350, 1200-1210 (2004). (Pubitemid 38339364)
7. Neoptolemos, J.P. et al. Adjuvant 5?fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC?1 and ?3(v1) trials. Br.J. Cancer 100, 246-250 (2009).
8. Neoptolemos, J.P. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304, 1073-1081 (2010).
9. Cunningham, D. et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.J. Clin. Oncol. 27, 5513-5518 (2009).
10. Stathis, A. & Moore, M.J. Advanced pancreatic carcinoma: current treatment and future challenges. Nat. Rev. Clin. Oncol. 7, 163-172 (2010).
11. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
12. Campbell, P.J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010).
13. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).
14. Haeno, H. et al. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148, 362-375 (2012).
15. Tuveson, D.A. & Neoptolemos, J.P. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 148, 21-23 (2012).
16. Rhim, A.D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361 (2012).
17. Collisson, E.A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500-503 (2011).
18. Burris, H.A. 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.J. Clin. Oncol. 15, 2403-2413 (1997).
19. Moore, M.J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.J. Clin. Oncol. 25, 1960-1966 (2007). (Pubitemid 46972777)
20. Dancey, J.E., Bedard, P.L., Onetto, N. & Hudson, T.J. The genetic basis for cancer treatment decisions. Cell 148, 409-420 (2012).
21. Tisdale, M.J. Cancer cachexia. Langenbecks Arch. Surg. 389, 299-305 (2004). (Pubitemid 39128544)
22. Felix, K. et al. Identification of serum proteins involved in pancreatic cancer cachexia. Life Sci. 88, 218-225 (2011).
23. Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N. Engl.J. Med. 364, 1817-1825 (2011).
24. Simon, R.M., Paik, S. & Hayes, D.F. Use of archived specimens in evaluation of prognostic and predictive biomarkers.J. Natl Cancer Inst. 101, 1446-1452 (2009).
25. Erkan, M. et al. The role of stroma in pancreatic cancer-diagnostic and therapeutic implications. Nat. Rev. Gastroenterol. Hepatol. http://dx.doi/org/ 10.1038/nrgastro.2012.115.
26. Marechal, R. et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res. 15, 2913-2919 (2009).
27. Farrell, J.J. et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136, 187-195 (2009).
28. Regine, W.F. et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299, 1019-1026 (2008). (Pubitemid 351347058)
29. Regine, W.F. et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5?year analysis of the, U.S. Intergroup/RTOG 9704 phase III trial. Ann. Surg. Oncol. 18, 1319-1326 (2011).
30. Oettle, H. et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297, 267-277 (2007). (Pubitemid 46143304)
31. Costello, E. & Neoptolemos, J. Enhancing the translation of cancer biomarkers. Br.J. Surg. 98, 1039-1040 (2011).
32. McShane, L.M. et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br.J. Cancer 93, 387-391 (2005). (Pubitemid 43080010)
33. Khleif, S.N., Doroshow, J.H. & Hait, W.N. AACR?FDA?NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin. Cancer Res. 16, 3299-3318 (2010).
34. Heinemann, V., Schulz, L., Issels, R.D. & Plunkett, W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin. Oncol. 22, 11-18 (1995).
35. Marechal, R. et al. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 116, 5200-5206 (2010).
36. Costantino, C.L. et al. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res. 69, 4567-4572 (2009).
37. Richards, N.G. et al. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann. Surg. 252, 499-505 (2010).
38. Valsecchi, M.E. et al. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? BMC Cancer 12, 104 (2012).
39. Hummel, R., Hussey, D.J. & Haier, J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur.J. Cancer 46, 298-311 (2010).
40. Frampton, A.E. et al. microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma. Expert Rev. Anticancer Ther. 11, 1837-1842 (2011).
41. Giovannetti, E. et al. MicroRNA?21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70, 4528-4538 (2010).
42. Hwang, J.H. et al. Identification of microRNA?21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 5, e10630 (2010).
43. Preis, M. et al. MicroRNA?10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 17, 5812-5821 (2011).
44. Bauer, A.S. et al. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS ONE 7, e34151 (2012).
45. Miyazono, F. et al. Molecular detection of circulating cancer cells during surgery in patients with biliary-pancreatic cancer. Am.J. Surg. 177, 475-479 (1999). (Pubitemid 29331477)
46. de Albuquerque, A. et al. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncology 82, 3-10 (2012).
47. Kurihara, T. et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result.J. Hepatobiliary Pancreat. Surg. 15, 189-195 (2008). (Pubitemid 351516978)
48. Olmos, D. et al. Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin. Cancer Res. 17, 5188-5196 (2011).
49. Neesse, A. et al. Stromal biology and therapy in pancreatic cancer. Gut 60, 861-868 (2010).
50. Polyak, K., Haviv, I. & Campbell, I.G. Co-evolution of tumor cells and their microenvironment. Trends Genet. 25, 30-38 (2009).
51. Whiteside, T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904-5912 (2008).
52. Hwang, R.F. et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68, 918-926 (2008). (Pubitemid 351206771)
53. Olive, K.P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
54. Grippo, P.J. & Tuveson, D.A. Deploying mouse models of pancreatic cancer for chemoprevention studies. Cancer Prev. Res. (Phila.) 3, 1382-1387 (2010).
55. Infante, J.R. et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.J. Clin. Oncol. 25, 319-325 (2007). (Pubitemid 350003021)
56. Von Hoff, D.D. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.J. Clin. Oncol. 29, 4548-4554 (2011).
57. Frese, K.K. et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2, 261-269 (2012).
58. Klimstra, D.S. & Longnecker, D.S. K?ras mutations in pancreatic ductal proliferative lesions. Am.J. Pathol. 145, 1547-1550 (1994). (Pubitemid 24378508)
59. Collins, M.A. et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.J. Clin. Invest. 122, 639-653 (2012).
60. Grocock, C.J. et al. The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families. Gut 59, 357-363 (2010).
61. Yan, L. et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 128, 2124-2130 (2005). (Pubitemid 40824719)
62. Rowinsky, E.K., Windle, J.J. & Von Hoff, D.D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development.J. Clin. Oncol. 17, 3631-3652 (1999). (Pubitemid 29517936)
63. Porzner, M. & Seufferlein, T. Novel approaches to target pancreatic cancer. Curr. Cancer Drug Targets 11, 698-713 (2011).
64. Bendell, J. & Goldberg, R.M. Targeted agents in the treatment of pancreatic cancer: history and lessons learned. Curr. Opin. Oncol. 19, 390-395 (2007). (Pubitemid 46883532)
65. da Cunha Santos, G. et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 116, 5599-5607 (2010).
66. Jimeno, A. et al. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res. 68, 2841-2849 (2008). (Pubitemid 351556283)
67. RTOG 0848 protocol information. Radiation Therapy Oncology Group [online], http:// www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx? study=0848 (2012).
68. Lowery, M.A. & O'Reilly, E.M. New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy. BioDrugs 25, 207-216 (2011).
69. Middleton, G., Ghaneh, P., Costello, E., Greenhalf, W. & Neoptolemos, J.P. New Treatment options for advanced pancreatic cancer. Expert Rev. Gastroenterol. Hepatol. 2, 673-696 (2008).
70. Kindler, H.L. et al. A placebo-controlled, randomized phase II study of conatumumab (C) or AMG, 479 (A) or placebo (P) plus gemcitabine (G.) in patients (pts) with metastatic pancreatic cancer (mPC) [abstract]. J. Clin. Oncol. a4035 (2010).
71. Nguyen, L.V., Vanner, R., Dirks, P. & Eaves, C.J. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 12, 133-143 (2012).
72. McCubrey, J.A. et al. Targeting the cancer initiating cell: the ultimate target for cancer therapy. Curr. Pharm. Des. 18, 1784-1795 (2012).
73. Shah, A.N. et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 14, 3629-3637 (2007). (Pubitemid 350160137)
74. Li, C. et al. CMet is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141, 2218-2227 e5 (2011).
75. Ranganathan, P., Weaver, K.L. & Capobianco, A.J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer 11, 338-351 (2011).
76. Ristorcelli, E. & Lombardo, D. Targeting Notch signaling in pancreatic cancer. Expert Opin. Ther. Targets 14, 541-552 (2010).
77. Wang, Z. et al. Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res. 31, 1105-1113 (2011).
78. Plentz, R. et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 136, 1741-1749 (2009).
79. Cook, N. et al. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.J. Exp. Med. 209, 437-444 (2012).
80. Morris, J.P. 4th, Wang, S.C. & Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 10, 683-695 (2010).
81. Hidalgo, M. & Maitra, A. The hedgehog pathway and pancreatic cancer.N. Engl.J. Med. 361, 2094-2096 (2009).
82. Olson, P. & Hanahan, D. Cancer. Breaching the cancer fortress. Science 324, 1400-1401 (2009).
83. Feldmann, G. et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 57, 1420-1430 (2008).
84. Feldmann, G. et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol. Cancer Ther. 7, 2725-2735 (2008).
85. Stephenson, J. et al. The safety of IPI?926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer [abstract 4114]. J. Clin. Oncol. 29 (2011).
86. Infinity reports update from phase 2 study of saridegib plus gemcitabine in patients with metastatic pancreatic cancer. Infinity Pharmaceuticals [online], http:// phx.corporate-ir.net/phoenix.zhtml?c=121941p=irol- newsArticleID=1653550highlight (2012).
87. Beatty, G.L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616 (2011).
88. Hahn, S.A. et al. BRCA2 germline mutations in familial pancreatic carcinoma.J. Natl Cancer Inst. 95, 214-221 (2003). (Pubitemid 36240634)
89. Bartsch, D.K., Gress, T.M. & Langer, P. Familial pancreatic cancer-current knowledge. Nat. Rev. Gastroenterol. Hepatol. http://dx.doi/org/ 10.1038/nrgastro.2012.111.
90. Rouleau, M., Patel, A., Hendzel, M.J., Kaufmann, S.H. & Poirier, G.G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10, 293-301 (2010).
91. Fogelman, D.R. et al. Evidence for the efficacy of Iniparib, a PARP?1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res. 31, 1417-1420 (2011).
92. US National Library of Medicine. Study to assess the safety and tolerability of a PARP inhibitor in combination with gemcitabine in pancreastic cancer. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT00515866 (2012).
93. Sawai, H. et al. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res. 65, 11536-11544 (2005). (Pubitemid 41821712)
94. Ito, Y. et al. Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers. Surgery 138, 788-794 (2005). (Pubitemid 41546203)
95. Wells, S.A. Jr et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.J. Clin. Oncol. 30, 134-141 (2012).
96. US National Library of Medicine. Clinical trial comparing gemcitabine and vandetanib therapy with gemcitabine alone in pancreatic cancer. ClinicalTrial.gov [online], http://clinicaltrials.gov/ct2/show/NCT01601808 (2012).